{
    "id": "5c663afe7c78d69471000013",
    "question": "Is pacritinib effective for treatment of myelofibrosis?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to consider the available information about pacritinib and its use in treating myelofibrosis. Pacritinib is a JAK1 and JAK2 inhibitor, which are both relevant to the pathogenesis of myelofibrosis. Myelofibrosis is characterized by the development of obliterative marrow fibrosis, which reduces bone marrow hematopoiesis and leads to cytopenias and extramedullary hematopoiesis. The underlying driver in almost all cases of myelofibrosis is JAK-STAT signaling, and JAK2 mutations are present in 50-60% of cases. Given this, a JAK inhibitor would be a reasonable treatment option for myelofibrosis. Pacritinib has been investigated in clinical trials for the treatment of myelofibrosis and has shown efficacy in reducing splenomegaly and alleviating constitutional symptoms. However, the available information does not explicitly state that pacritinib is approved for the treatment of myelofibrosis. Therefore, we must consider the available options and choose the most appropriate answer based on the information provided.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "Pathology_Robbins_2935",
            "title": "Pathology_Robbins",
            "content": "Primary myelofibrosis is more difficult to treat than polycythemia vera and CML. The median survival is in the range of 4 to 5 years. Threats to life include infection, thrombosis and bleeding related to platelet abnormalities, and transformation to AML, which occurs in 5% to 20% of cases. JAK2 inhibitors are effective at decreasing the splenomegaly and constitutional symptoms, even in those without JAK2 mutations, presumably because increased JAK/STAT signaling is common to all molecular subtypes. Hematopoietic stem cell transplantation may be curative in those young and fit enough to withstand the procedure. Myeloidtumorsoccurmainlyinadultsandfallintothreemajorgroups: \u2022Aggressivetumorscomprisedofimmaturemyeloidlineageblasts,whichreplacethemarrowandsuppressnormalhematopoiesis \u2022Associatedwithdiverseacquiredmutationsthatleadtoexpressionofabnormaltranscriptionfactors,whichinterferewithmyeloiddifferentiation"
        },
        {
            "id": "Immunology_Janeway_4035",
            "title": "Immunology_Janeway",
            "content": "example, tofacitinib inhibits JAK3, interfering with signaling by IL-2 and IL-4, and somewhat more weakly JAK1, interfering with signaling by IL-6. Tofacitinib is approved for treatment of rheumatoid arthritis. Ruxolitinib inhibits JAK1 and JAK2 and has been approved for treating myelofibrosis, an abnormal proliferation of bone marrow progenitor cells that causes fibrosis."
        },
        {
            "id": "Pathology_Robbins_2929",
            "title": "Pathology_Robbins",
            "content": "Unfortunately, prolonged survival has shown a propensity for polycythemia vera to evolve to a \u201cspent phase\u201d resembling primary myelofibrosis. After an average interval of 10 years, 15% to 20% of cases undergo such a transformation. Owing to the extensive marrow fibrosis, hematopoiesis shifts to the spleen, which enlarges markedly. Inhibitors that target JAK2 have been approved for treatment of the spent phase of polycythemia vera and lead to some improvement in most patients. Transformation to a \u201cblast crisis\u201d identical to AML also occurs, but much less frequently than in CML. The hallmark of primary myelofibrosis is the development ofobliterativemarrowfibrosis,whichreducesbonemarrow hematopoiesis and leads to cytopenias and extensive extramedullary hematopoiesis. Histologically, the appearance is identical to the spent phase that occurs occasionally late in the course of other myeloproliferative disorders. This similarity also extends to the underlying pathogenesis."
        },
        {
            "id": "Pathology_Robbins_2930",
            "title": "Pathology_Robbins",
            "content": "JAK-STAT signaling seems to be the underlying driver in almost all cases. Thus, JAK2 mutations are present in 50% to 60% of cases and activating mutations in MPL, the thrombopoietin receptor, are seen in an additional 1% to 5% of cases. Most of the remaining cases have other mutations, which also are hypothesized to stimulate increased JAK-STAT signaling. Why JAK2 mutations are associated with polycythemia vera in some patients and primary myelofibrosis in others is not understood; differences in the cell of origin and the genetic backgrounds that give rise to these two disorders are suspected."
        },
        {
            "id": "InternalMed_Harrison_8569",
            "title": "InternalMed_Harrison",
            "content": "The bone marrow is hypercellular with marked myeloid hyperplasia and a high myeloid-to-erythroid ratio of 15\u201320:1. Marrow blasts are 5% or less; when higher, they carry a worse prognosis or represent acceleration (if they are \u226515%). Increased reticulin fibrosis (by Snook\u2019s silver stain) is common, with 30\u201340% of patients demonstrating grade 3\u20134 reticulin fibrosis. This was considered adverse in the pre-TKI era. With TKI therapy, reticulin fibrosis resolves in most patients and is not an indicator of poor prognosis. Collagen fibrosis (Wright-Giemsa stain) is rare at diagnosis. Disease progression with a \u201cspent phase\u201d of myelofibrosis (myelophthisis, or burnt-out marrow) was common with busulfan therapy (20\u201330%) but is rare with TKI therapy."
        },
        {
            "id": "Pharmacology_Katzung_6122",
            "title": "Pharmacology_Katzung",
            "content": "Owing to thalidomide\u2019s serious toxicity profile, considerable effort has been expended in the development of analogs. Immunomodulatory derivatives of thalidomide are termed IMiDs. Some IMiDs are much more potent than thalidomide in regulating cytokines and affecting T-cell proliferation. Lenalidomide is an oral IMiD that in animal and in vitro studies has been shown to be similar to thalidomide in action, but with less toxicity, especially teratogenicity. Lenalidomide was approved by the FDA when trials showed its effectiveness in the treatment of the myelodysplastic syndrome with the chromosome 5q31 deletion. Clinical trials using lenalidomide to treat multiple myeloma showed similar efficacy, leading to approval for both primary and relapsed/refractory myeloma. Pomalidomide (originally called CC-4047) is a newer oral IMiD that is FDA approved. Like the other IMiDs, it has myriad mechanisms of actions including antiangiogenic activity, inhibition of TNF-\u03b1, and stimulation of"
        },
        {
            "id": "Pathology_Robbins_2916",
            "title": "Pathology_Robbins",
            "content": "CML is separated from the others by its association with a characteristic abnormality, the BCR-ABL fusion gene, which produces a constitutively active BCR-ABL tyrosine kinase. The most common genetic abnormalities in the \u201cBCRABL\u2013negative\u201d myeloproliferative neoplasms are activating mutations in the tyrosine kinase JAK2, which occur in virtually all cases of polycythemia vera and about 50% of cases of primary myelofibrosis and essential thrombocythemia Some rare myeloproliferative neoplasms are associated with activating mutations in other tyrosine kinases, such as platelet-derived growth factor receptor-\u03b1 and platelet-derived growth factor receptor-\u03b2."
        },
        {
            "id": "InternalMed_Harrison_8422",
            "title": "InternalMed_Harrison",
            "content": "(32P) are leukemogenic in PV, and their use should be avoided. If a cytotoxic agent must be used, hydroxyurea is preferred, but this drug does not prevent either thrombosis or myelofibrosis in PV, is itself leukemogenic, and should be used for as short a time as possible. Previously, PV patients with massive splenomegaly unresponsive to reduction by chemotherapy or interferon required splenectomy. However, with the introduction of the nonspecific JAK2 inhibitor ruxolitinib, it has been possible in the majority of patients with PV complicated by myelofibrosis and myeloid metaplasia to reduce spleen size while at the same time alleviating constitutional symptoms to due to cytokine release. This drug is currently undergoing clinical trials in PV patients intolerant of hydroxyurea. In some patients with end-stage disease, pulmonary hypertension may develop due to fibrosis or extramedullary hematopoiesis. A role for allogeneic bone marrow transplantation in PV has not been defined."
        },
        {
            "id": "Pharmacology_Katzung_5972",
            "title": "Pharmacology_Katzung",
            "content": "Nilotinib is a second-generation phenylamino-pyrimidine molecule that inhibits Bcr-Abl, c-kit, and PDGFR-\u03b2 tyrosine kinases. It has a higher binding affinity (up to 20to 50-fold) for the Abl kinase when compared with imatinib, and it overcomes imatinib resistance resulting from Bcr-Abl mutations. It was originally approved for chronic phase and accelerated phase CML with resistance or intolerance to prior therapy that included imatinib and was recently approved as first-line therapy of chronic phase CML. Bosutinib is a potent inhibitor of the Bcr-Abl tyrosine kinase, and it retains activity in 16 of 18 imatinib-resistant Bcr-Abl mutations. However, it is not effective against T315I and V299L mutations, which reside within the ATP-binding domain of the Abl tyrosine kinase. It is currently approved for the treatment of adult patients with chronic, accelerated, or blast phase Ph chromosome\u2013 positive CML with resistance or intolerance to prior therapy."
        },
        {
            "id": "InternalMed_Harrison_6384",
            "title": "InternalMed_Harrison",
            "content": "Ibrutinib is representative a novel class of inhibitors directed at Bruton\u2019s tyrosine kinase, which is important in the function of B cells. Initially approved for use in mantle cell lymphoma, it is potentially applicable to a number of B cell neoplasms that depend on signals through the B cell antigen receptor. Janus kinases likewise function downstream of a variety of cytokine receptors to amplify cytokine signals, and Janus kinase inhibitors including ruxolitinib have approved activity in myelofibrosis to ameliorate splenomegaly and systemic symptoms. Vorinostat is an inhibitor of histone deacetylases, which are responsible for maintaining the proper orientation of histones on DNA, with resulting capacity for transcriptional readiness. Acetylated histones allow access of transcription factors to target genes and therefore"
        },
        {
            "id": "Surgery_Schwartz_10081",
            "title": "Surgery_Schwartz",
            "content": "disorder characterized by an increase in red blood cell mass, frequently accompanied by leukocytosis, thrombocytosis, and splenomegaly. Patients with PV typically enjoy longer survival than those affected by hematologic malignancies but remain at risk for transformation to myelofibrosis or AML. The disease is rare, with an annual incidence of 5 to 17 cases per million population.76,77 Physical findings include ruddy cyanosis, conjunctival plethora, hepato-megaly, splenomegaly, and hypertension. Treatment should be tailored to the risk status of the patient and ranges from phle-botomy and aspirin administration to the use of chemothera-peutic agents. As in ET, splenectomy is not helpful in the early stages of disease and is best reserved for patients with late-stage disease in whom myeloid metaplasia has developed and spleno-megaly-related symptoms are severe.76,77Myelofibrosis (Agnogenic Myeloid Metaplasia) The term myelofibrosis may be used to describe either the generic condi-tion"
        },
        {
            "id": "Surgery_Schwartz_10180",
            "title": "Surgery_Schwartz",
            "content": "for non-Hodgkin\u2019s lymphoma. Oncol Rev. 2015;9(1):274. 72. Weledji EP. Benefits and risks of splenectomy. Int J Surg. 2014;12(2):113-119. 73. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484-495. 74. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012;87(11):1037-1045. 75. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(3):285-293. 76. Logan MS, Watson CM, Nottingham JM. Symptomatic sple-nomegaly in polycythemia vera: a review of the indications for splenectomy and perioperative considerations. Am Surg. 2009;75(5):363-368. 77. Tefferi A. How I treat myelofibrosis. Blood. 2011;117(13): 3494-3504. 78. Mesa R. Myeloproliferative disorder-associated massive sple-nomegaly. Clin Adv Hematol Oncol. 2008;6(4):278, 281-272. 79. Cervantes F. Myelofibrosis: biology and treatment options. Eur J"
        },
        {
            "id": "Surgery_Schwartz_10075",
            "title": "Surgery_Schwartz",
            "content": "myeloid leukemia, chronic myelomono-cytic leukemia, essential thrombocythemia, polycythemia vera, and myelofibrosis, also known as agnogenic myeloid metaplasia (see \u201cMyelofibrosis [Agnogenic Myeloid Metaplasia]\u201d later in this chapter). The common underlying problem leading to sple-nectomy in these disorders is symptomatic splenomegaly. Symp-toms due to splenomegaly are due to mass effect and consist of early satiety, poor gastric emptying, heaviness or pain in the left upper quadrant, and even diarrhea. Hypersplenism, when it occurs in these conditions, usually is associated with splenomeg-aly. Splenectomy performed in the setting of the myeloprolifera-tive disorders is generally for treatment of the pain, early satiety, and other symptoms of splenomegaly. Radiation has been used since 1903 to treat symptomatic splenomegaly in myeloprolif-erative disorders, but today it is principally used in situations in which splenectomy is not an option.Chronic Myelogenous Leukemia Chronic"
        },
        {
            "id": "InternalMed_Harrison_8421",
            "title": "InternalMed_Harrison",
            "content": "von Willebrand factor (VWF) multimers by the expanded platelet mass. Symptomatic splenomegaly can be treated with pegylated IFN-\u03b1. Pegylated IFN-\u03b1 can also produce complete hematologic and molecular remissions in PV, and its role in this disorder is currently under investigation. Anagrelide, a phosphodiesterase inhibitor, can reduce the platelet count and, if tolerated, is preferable to hydroxyurea because it lacks marrow toxicity and is protective against venous thrombosis. A reduction in platelet number may be necessary for the treatment of erythromelalgia or ocular migraine if salicylates are not effective or if the platelet count is sufficiently high to increase the risk of hemorrhage but only to the degree that symptoms are alleviated. Alkylating agents and radioactive sodium phosphate (32P) are leukemogenic in PV, and their use should be avoided. If a cytotoxic agent must be used, hydroxyurea is preferred, but this drug does not prevent either thrombosis or myelofibrosis in PV,"
        },
        {
            "id": "Pharmacology_Katzung_5989",
            "title": "Pharmacology_Katzung",
            "content": "Sunitinib is similar to sorafenib in that it inhibits multiple RTKs, although the specific types are somewhat different. They include PDGFR-\u03b1 and PDGFR-\u03b2, VEGF-R1, VEGF-R2, VEGFR3, and c-kit. It is approved for the treatment of advanced renal cell cancer and for the treatment of gastrointestinal stromal tumors after disease progression on or with intolerance to imatinib. Pazopanib is a small molecule that inhibits multiple RTKs, especially VEGF-R2 and VEGF-R3, PDGFR-\u03b2, and raf kinase. This oral agent is approved for the treatment of advanced renal cell cancer."
        },
        {
            "id": "InternalMed_Harrison_8440",
            "title": "InternalMed_Harrison",
            "content": "is attempted. Allopurinol can control significant hyperuricemia, and bone pain can be alleviated by local irradiation. The role of IFN-\u03b1 is still undefined; its side effects are more pronounced in the older individuals, and it may exacerbate the bone marrow failure. The JAK2 inhibitor, ruxolitinib, has proved effective in reducing splenomegaly and alleviating constitutional symptoms in a majority of advanced PMF patients while also prolonging survival, although it does not significantly influence the JAK2 V617F allele burden. Although anemia and thrombocytopenia are its major side effects, these are dose-dependent, and with time, anemia stabilizes and thrombocytopenia may improve. Allogeneic bone marrow transplantation is the only curative treatment for PMF and should be considered in younger patients; nonmyeloablative conditioning regimens may permit hematopoietic cell transplantation to be extended to older individuals, but this approach is currently under investigation."
        },
        {
            "id": "Pharmacology_Katzung_6007",
            "title": "Pharmacology_Katzung",
            "content": "Most patients with multiple myeloma are symptomatic at the time of initial diagnosis and require treatment with cytotoxic chemotherapy. Treatment with the combination of the alkylating agent melphalan and prednisone (MP protocol) has been a standard regimen for nearly 30 years. About 40% of patients respond to the MP combination, and the median duration of remission is 2\u20132.5 years. In patients who are considered candidates for high-dose therapy with stem cell transplantation, melphalan and other alkylating agents are to be avoided, as they can affect the success of stem cell harvesting."
        },
        {
            "id": "InternalMed_Harrison_8424",
            "title": "InternalMed_Harrison",
            "content": "Chronic PMF (other designations include idiopathic myelofibrosis, agnogenic myeloid metaplasia, or myelofibrosis with myeloid metaplasia) is a clonal disorder of a multipotent hematopoietic progenitor cell of unknown etiology characterized by marrow fibrosis, extramedullary hematopoiesis, and splenomegaly. PMF is the least common chronic MPN, and establishing this diagnosis in the absence of a specific clonal marker is difficult because myelofibrosis and splenomegaly are also features of both PV and CML. Furthermore, myelofibrosis and splenomegaly also occur in a variety of benign and malignant disorders (Table 131-3), many of which are amenable to specific therapies not effective in PMF. In contrast to the other chronic MPNs and so-called acute or malignant myelofibrosis, which can occur at any age, PMF primarily afflicts men in their sixth decade or later."
        },
        {
            "id": "InternalMed_Harrison_20236",
            "title": "InternalMed_Harrison",
            "content": "this variant is often responsive to imatinib; and (3) the FIP1-negative variant associated with clonal eosinophilia and at least four of the following: dysplastic peripheral eosinophils, increased serum vitamin B12, increased tryptase, anemia, thrombocytopenia, splenomegaly, bone marrow cellularity >80%, spindle-shaped mast cells, and myelofibrosis."
        },
        {
            "id": "Surgery_Schwartz_10079",
            "title": "Surgery_Schwartz",
            "content": "152823/02/19 2:36 PM 1529THE SPLEENCHAPTER 34Chronic Myelomonocytic Leukemia Like CML and AML, chronic myelomonocytic leukemia (CMML) is characterized by a proliferation of hematopoietic elements in the bone marrow and blood. CMML differs from CML in that it is associated with monocytosis in the peripheral smear (>1 \u00d7 103 monocytes/mm3) and in the bone marrow. Splenomegaly occurs in one-half of these patients, and splenectomy can result in symptomatic relief.75Essential Thrombocythemia Essential thrombocythemia (ET) represents abnormal growth of the megakaryocyte cell line, resulting in increased levels of platelets in the bloodstream. The diagnosis is made after the exclusion of other chronic myeloid disorders such as CML, polycythemia vera, and myelofibrosis that may also present with thrombocytosis.76 Clinical manifesta-tions of ET include vasomotor symptoms, thrombohemorrhagic events, recurrent fetal loss, and the transformation to myelofi-brosis with myeloid metaplasia or"
        },
        {
            "id": "Pharmacology_Katzung_6011",
            "title": "Pharmacology_Katzung",
            "content": "as it is able to overcome resistance to bortezomib, and preclinical and clinical studies suggest that it has broad-spectrum activity in hematologic malignancies and solid tumors. Ixazomib is the newest proteosome inhibitor to be approved in multiple myeloma, and in contrast to the other proteosome inhibitors, it is orally administered with good oral bioavailability. This agent can cause peripheral sensory neuropathy, but it is also associated with GI toxicity in the form of diarrhea and nausea and vomiting, thrombocytopenia, and hepatotoxicity."
        },
        {
            "id": "Surgery_Schwartz_10415",
            "title": "Surgery_Schwartz",
            "content": "being investigated for the treatment of soft tissue sarcomas. Among these are tyrosine kinase inhibitors (e.g., imatinib, suni-tinib, sorafenib, and dasatinib) that have been developed and approved for treatment of GIST. Clinical data accumulated in phase 2 trials also support the use of tyrosine kinase inhibitors (e.g., imatinib, sorafenib, and sunitinib) in the management of other advanced sarcomas.128 Anti\u2013vascular endothelial growth factor antibodies such as bevacizumab have demonstrated activity in patients with metastatic or unresectable angiosar-coma, solitary fibrous tumor, and epithelioid hemangioendo-thelioma.138 Pazopanib is an oral angiogenesis inhibitor that targets vascular endothelial growth factor receptors, platelet-derived growth factor receptor (PDGFR), and c-kit. In a recent phase 3 study, pazopanib showed efficacy against placebo in second or further line of therapy in patients with advanced soft tissue sarcoma.139 Inhibitors of the mammalian target of rapamycin"
        },
        {
            "id": "InternalMed_Harrison_8393",
            "title": "InternalMed_Harrison",
            "content": "can produce fibrosis. Secondary myelofibrosis is a late consequence of radiation therapy or treatment with radiomimetic drugs. Usually the infectious or malignant underlying processes are obvious. Marrow fibrosis can also be a feature of a variety of hematologic syndromes, especially chronic myeloid leukemia, multiple myeloma, lymphomas, myeloma, and hairy cell leukemia. The pathophysiology has three distinct features: proliferation of fibroblasts in the marrow space (myelofibrosis); the extension of hematopoiesis into the long bones and into extramedullary sites, usually the spleen, liver, and lymph nodes (myeloid metaplasia); and ineffective erythropoiesis. The etiology of the fibrosis is unknown but most likely involves dysregulated production of growth factors: platelet-derived growth factor and transforming growth factor \u03b2 have been implicated. Abnormal regulation of other hematopoietins would lead to localization of blood-producing cells in nonhematopoietic tissues and"
        },
        {
            "id": "Pharmacology_Katzung_6010",
            "title": "Pharmacology_Katzung",
            "content": "Bortezomib was first approved for use in relapsing or refractory multiple myeloma and is now widely used as first-line therapy. This agent is thought to exert its main cytotoxic effects through inhibition of the 26S proteosome, resulting in downregulation of the nuclear factor kappa B (NF-\u03baB) signaling pathway, which is thought to be a major signaling pathway for this disease. Of note, inhibition of NF-\u03baB has also been shown to restore chemosensitivity. One potential advantage of bortezomib is that it can be administered by the intravenous or subcutaneous route. Carfilzomib is an epoxyketone 26S proteosome inhibitor that is approved for patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent. This agent is important as it is able to overcome resistance to bortezomib, and preclinical and clinical studies suggest that it has broad-spectrum activity in hematologic malignancies and solid tumors. Ixazomib is the"
        },
        {
            "id": "Surgery_Schwartz_10082",
            "title": "Surgery_Schwartz",
            "content": "metaplasia has developed and spleno-megaly-related symptoms are severe.76,77Myelofibrosis (Agnogenic Myeloid Metaplasia) The term myelofibrosis may be used to describe either the generic condi-tion of fibrosis of the bone marrow (which may be associated with a number of benign and malignant disorders) or a specific, chronic, malignant hematologic disease associated with sple-nomegaly, the presence of red blood cell and white blood cell progenitors in the bloodstream, marrow fibrosis, and extramed-ullary hematopoiesis, otherwise known as agnogenic myeloid metaplasia (AMM). AMM also can be referred to as myeloscle-rosis, idiopathic myeloid metaplasia, and osteosclerosis. In this chapter, the term myelofibrosis is synonymous with AMM.In AMM, fibrosis of the bone marrow is believed to be a response to a clonal proliferation of hematopoietic stem cells. Marrow failure is common. The true incidence of AMM is unknown due to the scarcity of epidemiologic data, but one study estimated its U.S."
        },
        {
            "id": "InternalMed_Harrison_6368",
            "title": "InternalMed_Harrison",
            "content": "to imatinib enters into the decision about when to refer patients with CML for consideration of transplant approaches. Nilotinib is a tyrosine protein kinase inhibitor with a similar spectrum of activity to imatinib, but with increased potency and perhaps better tolerance by certain patients. Dasatinib, another inhibitor of the p210bcr-abl oncoproteins, is active in certain mutant variants of p210bcr-abl that are refractory to imatinib and arise during therapy with imatinib or are present de novo. Dasatinib also has inhibitory action against kinases belonging to the src tyrosine protein kinase family; this activity may contribute to its effects in hematopoietic tumors and suggest a role in solid tumors where src kinases are active. The T315I mutant of p210bcr-abl is resistant to imatinib, nilotinib, bosutinib, and dasatinib; ponatinib has activity in patients with this p210bcr-abl variant, but ponatinib has noteworthy associated thromboembolic toxicity. Use of this class of targeted"
        },
        {
            "id": "InternalMed_Harrison_7107",
            "title": "InternalMed_Harrison",
            "content": "New Therapies Although prolonged survival has been reported in phase II trials using newer agents, such as bevacizumab plus Sorafenib vs placebo Raf, VEGFR, PDGFR 10.7 vs 7.9 Sorafenib vs placebo (Asians) Raf, VEGFR, PDGFR 6.5 vs 4.2 Abbreviations: PDGFR, platelet-derived growth factor receptor; Raf, rapidly accelerated fibrosarcoma; VEGFR vascular endothelial growth factor receptor."
        },
        {
            "id": "Surgery_Schwartz_10080",
            "title": "Surgery_Schwartz",
            "content": "with thrombocytosis.76 Clinical manifesta-tions of ET include vasomotor symptoms, thrombohemorrhagic events, recurrent fetal loss, and the transformation to myelofi-brosis with myeloid metaplasia or AML. Hydroxyurea is used to reduce thrombotic events in ET but does not alter transforma-tion to myelofibrosis or leukemia. Splenomegaly occurs in one-third to one-half of patients with ET. Splenectomy is not felt to be helpful in the early stages of ET and is best reserved for the later stages of disease, when myeloid metaplasia has devel-oped.69 Even in these circumstances, candidates should be cho-sen selectively because significant bleeding has been reported to complicate splenectomy in these patients.Polycythemia Vera Polycythemia vera (PV) is a clonal, chronic, progressive myeloproliferative disorder characterized by an increase in red blood cell mass, frequently accompanied by leukocytosis, thrombocytosis, and splenomegaly. Patients with PV typically enjoy longer survival than those"
        },
        {
            "id": "Pharmacology_Katzung_5983",
            "title": "Pharmacology_Katzung",
            "content": "Afatinib is a small molecule inhibitor of the tyrosine kinase domains associated with EGFR, HER2 and HER4, and causes inhibition of downstream ErbB signaling. It is approved for the first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 substitution mutations. The toxicities associated with this agent are similar to those seen with erlotinib. Osimertinib is a small molecule inhibitor approved in 2015 for the treatment of metastatic EGFR T790M mutant NSCLC following progression on or after EGFR tyrosine kinase inhibitor therapy. In addition to targeting the T790M mutant, this agent targets the L858R and exon 19 EGFR mutations. The adverse effect profile is similar to erlotinib and afatinib, but unique cardiac toxicities are associated with this agent, including QTc prolongation and cardiomyopathy. Bevacizumab, Ziv-Aflibercept, Ramucirumab, Sorafenib, Sunitinib, & Pazopanib"
        },
        {
            "id": "Surgery_Schwartz_10085",
            "title": "Surgery_Schwartz",
            "content": "system should be examined; testing should include measurement of coagulation factors V and VIII and fibrin split products, platelet count, and bleeding time. Low platelet counts may require administration of ste-roids and/or platelet transfusion at the time of surgery. Sple-nectomy provides durable, effective palliation for nearly all patients with AMM, although postoperative complications are more common in patients with AMM than in those with other hematologic indications. The Mayo Clinic recently published its 30-year experience with 314 myelofibrosis patients who underwent splenectomy. Nearly half of the operations (49%) were performed to alleviate the mechanical symptoms of sple-nomegaly; the remainder were undertaken to manage anemia, thrombocytopenia, or portal hypertension. Response to splenec-tomy was 76% overall at 1 year; overall complication rate was 28%, including 21 perioperative deaths.80 Thrombosis, hemor-rhage, and infection complications were common, with"
        },
        {
            "id": "InternalMed_Harrison_8416",
            "title": "InternalMed_Harrison",
            "content": "and by itself has no prognostic significance. In approximately 15% of patients, however, myelofibrosis is accompanied by significant extramedullary hematopoiesis, hepatosplenomegaly, and transfusion-dependent anemia, which are manifestations of stem cell failure. The organomegaly can cause significant mechanical discomfort, portal hypertension, and progressive cachexia. Although the incidence of acute nonlymphocytic leukemia is increased in PV, the incidence of acute leukemia in patients not exposed to chemotherapy or radiation therapy is low. Interestingly, chemotherapy, including hydroxyurea, has been associated with acute leukemia in JAK2 V617F\u2013 negative stem cells in some PV patients. Erythromelalgia is a curious syndrome of unknown etiology associated with thrombocytosis, primarily involving the lower extremities and usually manifested by erythema, warmth, and pain of the affected appendage and occasionally digital infarction. It occurs with a variable frequency and is usually"
        },
        {
            "id": "Pharmacology_Katzung_6038",
            "title": "Pharmacology_Katzung",
            "content": "from the emergence of the T790M gatekeeper mutation either de novo or following previous EGFR TKI therapy. In NSCLC that is ALK-positive, three new small molecules have been developed: crizotinib, ceritinib, and alectinib. Crizotinib is the first-generation ALK inhibitor, while ceritinib and alectinib have clinical efficacy in patients whose disease has progressed on or who have become intolerant to crizotinib."
        }
    ],
    "scores": [
        0.035590978387588554,
        0.028175355920104693,
        0.025860070191880587,
        0.02440854041064574,
        0.02434306885345659,
        0.023743076495370073,
        0.02343243268502855,
        0.02325651151904745,
        0.02050708021343882,
        0.020340624842417325,
        0.019049346879535557,
        0.018265221017514596,
        0.018000642880102863,
        0.017577673271143318,
        0.017317707013257366,
        0.016771929824561403,
        0.01672357327015539,
        0.016612399494983054,
        0.016271409749670618,
        0.01605392156862745,
        0.01571294559099437,
        0.01562592482983131,
        0.015584415584415586,
        0.015522691352449762,
        0.015518796992481203,
        0.015498373262348417,
        0.015262954155836974,
        0.015220189133232611,
        0.015214624551660304,
        0.015159345391903532,
        0.015156637367590715,
        0.015148247978436658
    ]
}